Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
February 2026
Expert Review of Neurotherapeutics
Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway
Spinal Muscular Atrophy
Apitegromab
February 2026
Treat-NMD International Conference
Understanding adult patient perspectives on the clinical meaningfulness of “any point differences” on the Hammersmith Functional Motor Scale–Expanded in SMA
Spinal Muscular Atrophy
Apitegromab
February 2026
Treat-NMD International Conference
Assessing the impact of “any point differences” or “stability” in the Hammersmith Functional Motor Scale–Expanded on activities of daily living in adult patients with SMA
Immuno-Oncology
Linavonkibart
January 2026
Linavonkibart publication
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Spinal Muscular Atrophy
Apitegromab
January 2026
British Paediatric Neurology Association Annual Conference
Trial design and rationale for OPAL, a phase 2, randomized, double-blind study of apitegromab in patients aged <2 years with spinal muscular atrophy
Spinal Muscular Atrophy
Apitegromab
January 2026
British Paediatric Neurology Association Annual Conference
